摘要 |
The invention relates to the new antibiotic Lysolipin including two components X and I, and derivatives thereof. Lysolipin is formed when the strain Streptomyces violaceoniger (Waksman et Curtis) Waksman et Henrici Tü 96, which strain has been deposited under the reference NRRL 8097 at the Northern Regional Laboratory, U.S. Department of Agriculture, Peoria, Illinois, is cultured in a nutrient medium. The structural formulae of the 2 components are <IMAGE> Lysolipin I <IMAGE> Lysolipin X Lysolipin I and X and their derivatives have antibacterial activity and are effective against yeast - like fungi, such as Candida albicans. Their antibiotic action probably depends on an inhibition of the cell wall synthesis.
|